Viridian Therapeutics Inc. Revenue 2013–2025
Viridian Therapeutics Inc. annual/quarterly revenue history and growth rate from 2013 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Viridian Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 141000, a 95.83% increase year-over-year.
- Viridian Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 70.9 M, a 23362.91% increase year-over-year.
- Viridian Therapeutics Inc. annual revenue for 2025 was 70.8 M, a 23359.93% increase from 2024.
- Viridian Therapeutics Inc. annual revenue for 2024 was 302000, a 3.82% decrease from 2023.
- Viridian Therapeutics Inc. annual revenue for 2023 was 314000, a 82.28% decrease from 2022.
- Viridian Therapeutics Inc. annual revenue for 2022 was 1.8 M.
Viridian Therapeutics Inc. (VRDN) — Frequently Asked Questions
Viridian Therapeutics Inc. (VRDN) is a publicly traded US company. It has a market capitalization of $1.64B. In fiscal 2025 it reported revenue of $71M and net income of -$343M. Explore VRDN's stock price, financial statements, earnings history, margins and key ratios below.
What is Viridian Therapeutics Inc.'s market cap?
Viridian Therapeutics Inc. (VRDN) has a market capitalization of $1.64B.
What is the VRDN stock price?
VRDN trades at $16.14 (+2.35% on the day).
How much revenue does Viridian Therapeutics Inc. make?
Viridian Therapeutics Inc. reported revenue of $71M in fiscal 2025.
Is VRDN profitable?
In fiscal 2025, Viridian Therapeutics Inc. reported net income of -$343M.